Biotech entity
pharma is the sole category represented across all 1 tracked stories. Jan van de Winkel is most often covered alongside Genmab A/S, which appears in 1 of these 1 story. They are less corroborated than the beat average, carrying 2 original sources each against 2.4 for the same window.
Last mentioned: Feb 19, 2026
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
pharma is the sole category represented across all 1 tracked stories. Jan van de Winkel is most often covered alongside Genmab A/S, which appears in 1 of these 1 story. They are less corroborated than the beat average, carrying 2 original sources each against 2.4 for the same window. Their average consequence score of 6 sits level with the 6 recorded across the beat in that window. We currently track 1 Biotech story that mention Jan van de Winkel, all published on February 19, 2026.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 27 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Jan van de Winkel. Shared-story counts are live from our verified record — not editorial picks.
Genmab reported full-year 2025 revenue of $3.72B, missing analyst estimates by $50M, while initiating a robust 2026 outlook focused on proprietary oncology assets. Despite a dip in full-year profit, the company is accelerating its transition from a royalty-dependent model to a self-sustaining commercial powerhouse.
Source: insidermonkey.com · seekingalpha.com
Jan van de Winkel is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
